SCHEMBL1667949

SCHEMBL1667949

O=C(O)c1csc(C(=O)CCCCc2ccccc2)n1

nearest known ligand 0.64

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
PLA2G4A P47712 2/20 0.64
CES1 P23141 8/20 0.58
NCEH1 Q6PIU2 1/20 0.48
DPP4 P27487 1/20 0.48
MAPT P10636 1/20 0.47
RXFP1 Q9HBX9 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12548449 0.92 PLA2G4A (0.59) PLA2G4ACES1NCEH1
SCHEMBL1667463 0.84 PLA2G4A (0.62) PLA2G4ACES1MAPT
SCHEMBL20662525 0.83 PLA2G4A (0.59) PLA2G4ACES1DPP4MAPTRXFP1
SCHEMBL22452062 0.82 CES1 (0.46) PLA2G4ACES1MAPT
SCHEMBL1667568 0.81 PLA2G4A (0.56) PLA2G4ACES1DPP4MAPTRXFP1
SCHEMBL12548644 0.80 CES1 (0.56) PLA2G4ACES1NCEH1
SCHEMBL1669644 0.78 PLA2G4A (1.00) PLA2G4AMAPT
SCHEMBL17368809 0.78 PLA2G4A (0.61) PLA2G4ACES1MAPT
SCHEMBL17368813 0.75 PLA2G4A (0.49) PLA2G4ACES1
SCHEMBL1667606 0.74 ALDH1A1 (0.52) PLA2G4ACES1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11691959-B2 Anti-inflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds AVEXXIN AS (NO) 2023-07-04 US disclosed
US-11691959-B2 Anti-inflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds AVEXXIN AS (NO) 2023-07-04 US disclosed
US-20220363659-A1 ANTI-INFLAMMATORY AND ANTITUMOR 2-OXOTHIAZOLES AND 2-OXOTHIOPHENES COMPOUNDS AVEXXIN AS (NO) 2022-11-17 US disclosed
US-10370344-B2 2-oxothiazole compounds and method of using same for chronic inflammatory disorders AVEXXIN AS (NO) 2019-08-06 US disclosed
US-10370344-B2 2-oxothiazole compounds and method of using same for chronic inflammatory disorders AVEXXIN AS (NO) 2019-08-06 US disclosed
US-10259801-B2 Anti-inflammatory and antitumor 2-oxothiazoles ABD 2-oxothiophenes compounds AVEXXIN AS (NO) 2019-04-16 US disclosed
EP-3431084-A1 ANTIINFLAMMATORY 2-OXOTHIAZOLES Avexxin AS (NO) 2019-01-23 EP disclosed
EP-3431084-A1 ANTIINFLAMMATORY 2-OXOTHIAZOLES Avexxin AS (NO) 2019-01-23 EP disclosed
US-20180105507-A1 ANTIIFLAMMATORY AND ANTITUMOR 2-OXOTHIAZOLES ABD 2-OXOTHIOPHENES COMPOUNDS AVEXXIN AS (NO) 2018-04-19 US disclosed
US-20180105507-A1 ANTIIFLAMMATORY AND ANTITUMOR 2-OXOTHIAZOLES ABD 2-OXOTHIOPHENES COMPOUNDS AVEXXIN AS (NO) 2018-04-19 US disclosed
CN-104892542-A ANTI INFLAMMATORY 2-OXOTHIAZOLES AND 2 -OXOOXAZOLES AVEXXIN AS 2015-09-09 CN disclosed
CN-102647984-B Anti-inflammatory 2-carbonylthiazoles and 2-carbonyloxazoles AVEXXIN AS 2015-03-25 CN disclosed
CN-103772312-A ANTI INFLAMMATORY 2-OXOTHIAZOLES AND 2 -OXOOXAZOLES AVEXXIN AS 2014-05-07 CN disclosed
CN-102647984-A Anti-inflammatory 2-carbonylthiazoles and 2-carbonyloxazoles AVEXXIN AS 2012-08-22 CN disclosed
EP-2482815-A1 ANTI INFLAMMATORY 2-OXOTHIAZOLES AND 2 -OXOOXAZOLES Avexxin AS (NO) 2012-08-08 EP disclosed
US-20110136879-A1 COMPOUND AVEXXIN AS (NO) 2011-06-09 US disclosed
US-20110136879-A1 COMPOUND AVEXXIN AS (NO) 2011-06-09 US disclosed
US-20110136879-A1 COMPOUND AVEXXIN AS (NO) 2011-06-09 US disclosed
WO-2011039365-A1 ANTI INFLAMMATORY 2-OXOTHIAZOLES AND 2 -OXOOXAZOLES AVEXXIN AS (NO) 2011-04-07 WO disclosed
WO-2011039365-A1 ANTI INFLAMMATORY 2-OXOTHIAZOLES AND 2 -OXOOXAZOLES AVEXXIN AS (NO) 2011-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110136879-A1 COMPOUND CBR1, CBR3, CCR1 PLA2G4A 1999/4885CES1 59/4885NCEH1 15/4885
US-20180105507-A1 ANTIIFLAMMATORY AND ANTITUMOR 2-OXOTHIAZOLES ABD 2-OXOTHIOPHENES COMPOUNDS FOXO1, FOXO3, BCOR PLA2G4A 446/4885CES1 1307/4885NCEH1 119/4885
US-10259801-B2 Anti-inflammatory and antitumor 2-oxothiazoles ABD 2-oxothiophenes compounds OXER1, CCL2, IL6 PLA2G4A 589/4885CES1 534/4885NCEH1 48/4885
US-20220363659-A1 ANTI-INFLAMMATORY AND ANTITUMOR 2-OXOTHIAZOLES AND 2-OXOTHIOPHENES COMPOUNDS OXER1, CASP1, IL6 PLA2G4A 1539/4885CES1 527/4885NCEH1 40/4885
US-11691959-B2 Anti-inflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds CASP1, IL1B, OXER1 PLA2G4A 1579/4885CES1 379/4885NCEH1 37/4885
US-10370344-B2 2-oxothiazole compounds and method of using same for chronic inflammatory disorders CX3CR1, LTC4S, CBR1 PLA2G4A 1174/4885CES1 155/4885NCEH1 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.